Merck & Co., Inc. (MRK)
NYSE: MRK · Real-Time Price · USD
82.71
+2.41 (3.00%)
At close: Aug 13, 2025, 4:00 PM
82.37
-0.34 (-0.41%)
After-hours: Aug 13, 2025, 7:58 PM EDT
Merck & Co. Revenue
Merck & Co. had revenue of $15.81B in the quarter ending June 30, 2025, a decrease of -1.90%. This brings the company's revenue in the last twelve months to $63.62B, up 1.82% year-over-year. In the year 2024, Merck & Co. had annual revenue of $64.17B with 6.74% growth.
Revenue (ttm)
$63.62B
Revenue Growth
+1.82%
P/S Ratio
3.28
Revenue / Employee
$848,213
Employees
75,000
Market Cap
206.59B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 64.17B | 4.05B | 6.74% |
Dec 31, 2023 | 60.12B | 832.00M | 1.40% |
Dec 31, 2022 | 59.28B | 10.58B | 21.72% |
Dec 31, 2021 | 48.70B | 7.19B | 17.31% |
Dec 31, 2020 | 41.52B | 2.40B | 6.13% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
Thermo Fisher Scientific | 43.21B |
MRK News
- 1 day ago - 10 Undervalued Dividend Growth Stocks: August 2025 - Seeking Alpha
- 1 day ago - KEYTRUDA® (pembrolizumab) plus Padcev® (enfortumab vedotin-ejfv) Significantly Improved Event-Free and Overall Survival and Pathologic Complete Response Rate for Certain Patients with Muscle-Invasive Bladder Cancer When Given Before and After Surgery - Business Wire
- 6 days ago - August Dogs Of The Dow Unleashed 19 'Safer' Dividend Buys - Seeking Alpha
- 7 days ago - Stock Picks From Seeking Alpha's July 2025 New Analysts - Seeking Alpha
- 8 days ago - Income Strategy: I'm Buying 2 Elite Mispriced Dividends - Seeking Alpha
- 11 days ago - 5 Relatively Secure And Cheap Dividend Stocks, Yields Up To 8.5% (August 2025) - Seeking Alpha
- 12 days ago - Pharmaceutical makers were largely unshaken by new demands from President Trump to lower drug prices, with experts saying the measures would either have modes impact or face legal challenges - WSJ
- 12 days ago - Top 10 High-Yield Dividend Stocks For August 2025 - Seeking Alpha